Article thumbnail

Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

By Lamberto Manzoli, Corrado De Vito, Georgia Salanti, Maddalena D'Addario, Paolo Villari and John P.A. Ioannidis
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). [Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1]. Zh Mikrobiol Epidemiol Immunobiol.
  2. (2010). A clinical study to assess the immunogenicity and safety of a monovalent
  3. (2009). A novel influenza A (H1N1) vaccine in various age groups.
  4. (1994). A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
  5. (2010). A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial.
  6. (2010). A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults.
  7. (2010). Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Meta-Analysis on (2009) H1N1
  8. (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.
  9. (2010). AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
  10. (2011). Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.
  11. (2004). Boccia A
  12. (1998). Can quality of clinical trials and meta-analyses be quantified?
  13. (2010). Checking consistency in mixed treatment comparison meta-analysis.
  14. Clinical Study Register - study n.
  15. (2004). Combination of direct and indirect evidence in mixed treatment comparisons.
  16. (2010). Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children.
  17. (2011). Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/ H1N1/2009 influenza vaccine administered to adults during two randomised controlled trials.
  18. (2008). Evaluation of networks of randomized trials.
  19. (1999). Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
  20. (2008). Exploring the geometry of treatment networks.
  21. (2011). FluView - 2010-2011 Influenza Season Week 15 ending
  22. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.
  23. (2007). Guidance for Industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines.
  24. (2010). Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.
  25. (2010). Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.
  26. (2010). Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
  27. (2009). Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis.
  28. (2010). Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
  29. (2010). Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
  30. (2010). Immunogenicity and safety of a novel AS03A-adjuvanted H1N1
  31. (2011). Immunogenicity and safety of a two-dose schedule of whole-virion and AS03(A)-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, agestratified, head-to-head trial.
  32. (2010). Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
  33. (2011). Immunogenicity and safety of influenza A
  34. (2011). Immunogenicity and safety of pandemic influenza A
  35. (2010). Immunogenicity associated with the routine use of an influenza A H1N1 vaccine in health care personnel in Guangzhou,
  36. (2010). Immunogenicity of a monovalent
  37. (2010). Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan.
  38. (2010). Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
  39. (2010). Influenza A
  40. (2011). Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial.
  41. (2009). Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments metaanalyses.
  42. (2010). Large trials confirm immunogenicity of H1N1 vaccines.
  43. (2003). Measuring inconsistency in meta-analyses.
  44. (2010). Medicines authorised during pandemic.
  45. (1986). Meta-analysis in clinical trials.
  46. (1997). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96).
  47. (2010). Pandemic (H1N1) 2009 - update 112.
  48. (2011). Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
  49. (2011). Panvax((R)): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A
  50. (2010). Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season: WHO.
  51. (2010). Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.
  52. (2009). Response to a monovalent 2009 influenza A (H1N1) vaccine.
  53. (2010). Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.
  54. (2010). Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
  55. (2010). Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
  56. (2010). Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study.
  57. (2010). Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to ,18 years of age: a prospective, open-label, multi-center trial.
  58. (2010). Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
  59. (2011). Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.
  60. (2011). Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
  61. (1959). Statistical aspects of the analysis of data from retrospective studies of disease.
  62. (2001). Systematic reviews in health care: Assessing the quality of controlled clinical trials.
  63. (2010). The
  64. (2007). The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey.
  65. (2006). The case of the misleading funnel plot.
  66. (2007). The efficacyofinfluenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality.
  67. (2007). Uncertainty in heterogeneity estimates in meta-analyses.